Point72 Asset Management’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-7,034,952
Closed -$151M 4122
2025
Q4
$151M Buy
7,034,952
+2,210,448
+46% +$38.8M 0.17% 100
2025
Q3
$56.5M Buy
4,824,504
+138,701
+3% +$1.38M 0.09% 241
2025
Q2
$43.6M Buy
4,685,803
+325,128
+7% +$2.67M 0.09% 271
2025
Q1
$29.3M Buy
4,360,675
+3,671,885
+533% +$35.2M 0.07% 337
2024
Q4
$7.31M Buy
688,790
+218,143
+46% +$2.64M 0.02% 819
2024
Q3
$6.88M Buy
470,647
+85,580
+22% +$1.22M 0.02% 780
2024
Q2
$4.66M Sell
385,067
-1,256,833
-77% -$19.7M 0.01% 850
2024
Q1
$40.5M Buy
1,641,900
+959,281
+141% +$19.5M 0.1% 249
2023
Q4
$7.3M Buy
682,619
+136,700
+25% +$1.14M 0.02% 791
2023
Q3
$4.56M Buy
545,919
+127,792
+31% +$939K 0.01% 905
2023
Q2
$3.31M Buy
+418,127
New +$2.29M 0.01% 939

Other funds holding IMNM

Point72 Asset Management's IMNM Position: Q1 2026 in Review

Point72 Asset Management sold out of Immunome (IMNM) in Q1 2026, closing a stake of 7,034,952 shares — an estimated $151M sold.

Point72 Asset Management first reported a position in IMNM in Q2 2023 and held it in 11 quarters. The position peaked at $151M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Point72 Asset Management reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 7,034,952 Immunome shares in Q1 2026, an estimated $151M.
  • Point72 Asset Management first reported a position in Immunome in Q2 2023 and held it in 11 quarters.
  • Point72 Asset Management's Immunome position peaked at $151M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.